Cost-Effectiveness of a Potential Group B Streptococcal Vaccine Program for Pregnant Women in South Africa
No licensed vaccine for group B Streptococcus (GBS) currently exists, but a polysaccharide-protein conjugate vaccine candidate is currently in trials. This article, published in Vaccine, reports the results of a study that evaluated the potential cost and health impacts of maternal GBS vaccination in South Africa using a decision-analytic model. The authors found that vaccination would substantially reduce the burden of GBS disease in South Africa and be very cost-effective. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Kim S-Y, Russell LB, Park J, et al.
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Kim S-Y, Russell LB, Park J, et al. Cost-Effectiveness of a Potential Group B Streptococcal Vaccine Program for Pregnant Women in South Africa. Vaccine. 2014;32(7):1954-1963.
Resource types: Peer-reviewed journal
Diseases/vaccines: Group B Streptococcus (GBS)